Vascular Aging After 40: What Your Heart and Brain Have in Common

Your latest cholesterol result cannot tell you how long your LDL has been elevated. That history can matter: research links cumulative LDL exposure to later coronary heart disease, even after accounting for the level measured in midlife. Zhang et al., Columbia University, 2021.

The connection with brain health needs more care. Blood-pressure trials have measured cognitive outcomes directly. Other research has examined proteins in ageing tissues or blood markers associated with Alzheimer’s disease. These studies ask different questions, and their answers should remain distinct.

What your cholesterol history adds

Vascular ageing describes changes in blood vessels over time. It overlaps with atherosclerosis, the accumulation of arterial plaque, but the terms are not interchangeable. A study of ageing vessel proteins does not answer the same question as a trial testing whether a treatment prevents cardiovascular events.

In a 2021 analysis involving 18,288 participants, Columbia University researchers found that cumulative LDL exposure during young adulthood and middle age was associated with subsequent coronary heart disease, independently of midlife LDL levels. The study was observational. It cannot establish when an individual should start treatment or how much they would benefit. It does suggest that older results can add context to today’s reading. Zhang et al., *JAMA Cardiology*, 2021.

Randomised trials provide stronger evidence about treatment effects. In FOURIER, 27,564 people with established cardiovascular disease received evolocumab or placebo alongside statin therapy. Over a median 2.2 years, the primary combined cardiovascular outcome occurred in 9.8% of the treatment group and 11.3% of the placebo group. That is an absolute difference of 1.5 percentage points in the population studied. It is not a forecast for a healthy 45-year-old. Sabatine et al., FOURIER investigators, *New England Journal of Medicine*, 2017.

For a discussion about treatment, both kinds of evidence have a place. Your history helps describe your risk; trial results help estimate what an intervention might achieve. Decisions still depend on your overall risk, likely absolute benefit, preferences and tolerability.

Blood pressure offers a more direct connection to cognition

SPRINT MIND tested intensive versus standard blood-pressure treatment in adults aged 50 or older with hypertension and elevated cardiovascular risk. People with diabetes or a previous stroke were excluded.

The original report found fewer cases of mild cognitive impairment with intensive treatment, but no statistically significant reduction in probable dementia. The trial had stopped early because of cardiovascular and mortality benefits, leaving fewer dementia cases than expected and limiting the certainty of that finding. SPRINT MIND investigators, *JAMA*, 2019.

Extended follow-up, published in 2025, found a lower risk of the combined outcome of mild cognitive impairment or probable dementia. Probable dementia considered alone was still not significantly reduced. Reboussin et al., Wake Forest University, *Neurology*, 2025.

A combined outcome counts either diagnosis. A reduction in that combined measure does not establish a reduction in each component separately. The findings support a cognitive benefit within the population studied, while leaving uncertainty about dementia prevention. They do not demonstrate prevention of Alzheimer’s disease.

The eligibility criteria also matter to you as a reader. These were monitored treatment strategies in a defined group of patients. Their targets are not universal instructions for adults over 40.

Could ageing vessels influence other tissues?

An emerging line of research asks whether blood vessels participate in ageing elsewhere in the body, beyond delivering blood.

A Chinese Academy of Sciences-led study published in Cell in 2025 analysed 516 samples from 13 human tissues. Researchers identified age-related protein changes that differed across tissues, with blood vessels showing early susceptibility. They also investigated candidate proteins that might contribute to vascular and systemic ageing. Ding et al., *Cell*, 2025.

This gives researchers reasons to investigate vessels as active participants in ageing. It does not establish that vascular ageing initiates every other organ’s decline. Comparing samples from people of different ages is also different from following the same person’s arteries over decades.

The research does not yet provide a validated personal “vascular age” score for guiding care. Nor does it show that changing a blood marker rejuvenates the body. Its immediate value is in identifying biological processes that can be tested further.

Obicetrapib and the distance between a marker and memory

Obicetrapib, a CETP inhibitor, illustrates why the outcome being measured matters.

In the 2025 BROADWAY trial, LDL fell by 29.9% from baseline at day 84 in the obicetrapib group, compared with a 2.7% increase with placebo. Participants had established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolaemia, an inherited cholesterol disorder. They were already receiving maximally tolerated lipid-lowering therapy. Nicholls et al., BROADWAY investigators, *New England Journal of Medicine*, 2025.

A prespecified substudy examined Alzheimer’s-related blood biomarkers in 1,535 participants. Over 12 months, obicetrapib attenuated the increase in p-tau217 compared with placebo. Published online in 2025 and in a 2026 journal issue, the study was funded by NewAmsterdam Pharma, the drug’s developer. Davidson et al., *Journal of Prevention of Alzheimer’s Disease*, 2026.

The substudy did not assess cognitive function or clinical outcomes. It therefore cannot tell us whether participants retained their memory for longer or developed dementia less often. A blood biomarker can help researchers decide what to investigate. Establishing a benefit that patients experience requires trials that measure that benefit.

What a personal record can reasonably tell you

Personal tracking has a narrower purpose than these studies. It can help you describe your history and discuss an agreed care plan. It cannot demonstrate that you have prevented dementia or reversed vascular ageing.

Previous lipid results and blood-pressure records are useful starting material. Keep their dates, values and units together, alongside medication changes and relevant family history. Leave missing periods visible. A few scattered measurements do not justify a precise lifetime exposure score.

Make repeated measurements comparable

If home blood-pressure monitoring forms part of your care, technique affects how useful the record will be. The American Heart Association recommends a validated upper-arm monitor with the correct cuff size. Its guidance includes at least five minutes of quiet rest, an arm supported at heart level, and two readings one minute apart. Avoid smoking, caffeine and exercise during the preceding 30 minutes, and agree on measurement frequency with your clinician. Record both readings. American Heart Association, reviewed 2025.

Home readings support clinical review; they are not a reason to stop prescribed medication without discussing it with your healthcare professional.

Be clear about the outcome

An average home blood pressure, a repeat lipid result and a record of completed walks describe different things. The walks record whether a habit happened. The measurements record changes in particular markers. Neither directly measures slower brain ageing.

If you experiment with a habit, record what changed and when. Include concurrent changes in sleep, illness or prescribed treatment. When several things change together, a personal record rarely allows you to identify which caused a later result.

For your next routine appointment, older results and one precise question may be enough: “What does my history add to the assessment we would make from today’s numbers?” Then establish which result the agreed plan is intended to change and when it should be reviewed.

Sources